Ebb & Flow

Actelion Ltd. (SIX:ATLN) lost CHF0.20 to CHF47.60 last week after FDA issued a complete response letter for an sNDA for Zavesca miglustat to treat progressive neurological manifestations in patients with Niemann-Pick type C disease. The agency asked for additional preclinical and clinical information(see B9).

Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) lost $0.96 to $20.26 on Friday after FDA missed Friday's PDUFA date for a decision on an NDA for exenatide once weekly to treat Type II diabetes. But the stock still was up $0.43 on the week. Exenatide uses drug delivery technology from Alkermes Inc. (NASDAQ:ALKS), which was off $0.43 to $12.21 on Friday and gained $0.01 on the week...